2.49
price down icon3.49%   -0.09
after-market Handel nachbörslich: 2.48 -0.01 -0.40%
loading
Schlusskurs vom Vortag:
$2.58
Offen:
$2.59
24-Stunden-Volumen:
210.49K
Relative Volume:
0.64
Marktkapitalisierung:
$58.29M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-94.11M
KGV:
-0.4143
EPS:
-6.01
Netto-Cashflow:
$-86.06M
1W Leistung:
+8.73%
1M Leistung:
+12.67%
6M Leistung:
-50.40%
1J Leistung:
-64.33%
1-Tages-Spanne:
Value
$2.335
$2.598
1-Wochen-Bereich:
Value
$2.14
$2.598
52-Wochen-Spanne:
Value
$1.78
$10.14

Adverum Biotechnologies Inc Stock (ADVM) Company Profile

Name
Firmenname
Adverum Biotechnologies Inc
Name
Telefon
(650) 649-1004
Name
Adresse
100 CARDINAL WAY, REDWOOD CITY, CA
Name
Mitarbeiter
155
Name
Twitter
@adverumbio
Name
Nächster Verdiensttermin
2024-11-07
Name
Neueste SEC-Einreichungen
Name
ADVM's Discussions on Twitter

Vergleichen Sie ADVM mit anderen Aktien

Aktien Preis Marktkapitalisierung Umsatz Nettogewinn Free Cashflow ENV
Biotechnology icon
ADVM
Adverum Biotechnologies Inc
2.49 58.29M 0 -94.11M -86.06M -6.01
Biotechnology icon
VRTX
Vertex Pharmaceuticals Inc
443.40 115.95B 11.10B -988.90M -1.26B -3.92
Biotechnology icon
REGN
Regeneron Pharmaceuticals Inc
521.00 56.52B 14.09B 4.50B 2.96B 39.28
Biotechnology icon
ALNY
Alnylam Pharmaceuticals Inc
318.25 39.44B 2.35B -269.70M -75.39M -2.09
Biotechnology icon
ARGX
Argen X Se Adr
560.04 35.14B 2.58B 1.06B -1.28B 16.33
Biotechnology icon
ONC
Beone Medicines Ltd Adr
254.49 28.51B 3.81B -644.79M -669.77M -6.24

Adverum Biotechnologies Inc Stock (ADVM) Upgrades & Downgrades

Datum Aktion Analytiker Ratingänderung
2024-06-25 Eingeleitet Oppenheimer Outperform
2024-04-30 Eingeleitet H.C. Wainwright Buy
2022-07-07 Hochstufung Truist Hold → Buy
2021-07-23 Herabstufung Cantor Fitzgerald Overweight → Neutral
2021-05-03 Herabstufung SVB Leerink Outperform → Mkt Perform
2021-04-29 Herabstufung Chardan Capital Markets Buy → Neutral
2021-04-29 Herabstufung RBC Capital Mkts Outperform → Sector Perform
2021-04-29 Herabstufung Truist Buy → Hold
2020-12-16 Eingeleitet UBS Neutral
2020-11-12 Hochstufung Raymond James Underperform → Mkt Perform
2020-06-26 Herabstufung Raymond James Mkt Perform → Underperform
2020-05-13 Eingeleitet RBC Capital Mkts Outperform
2020-05-05 Hochstufung SunTrust Hold → Buy
2020-04-28 Eingeleitet Goldman Buy
2020-03-16 Eingeleitet SVB Leerink Outperform
2020-02-10 Hochstufung Cantor Fitzgerald Neutral → Overweight
2020-02-10 Hochstufung Chardan Capital Markets Neutral → Buy
2019-10-15 Bestätigt Chardan Capital Markets Neutral
2019-09-13 Bestätigt Chardan Capital Markets Neutral
2019-06-14 Fortgesetzt Raymond James Mkt Perform
2018-11-02 Herabstufung Raymond James Outperform → Mkt Perform
2018-11-02 Herabstufung SunTrust Buy → Hold
2018-09-21 Eingeleitet Cantor Fitzgerald Overweight
2018-08-30 Eingeleitet SunTrust Buy
2018-02-15 Fortgesetzt Piper Jaffray Overweight
2017-10-12 Eingeleitet Raymond James Outperform
Alle ansehen

Adverum Biotechnologies Inc Aktie (ADVM) Neueste Nachrichten

pulisher
Jun 18, 2025

Adverum Biotechnologies shareholders approve stock option repricing - Investing.com

Jun 18, 2025
pulisher
Jun 18, 2025

Adverum Biotechnologies shareholders approve stock option repricing By Investing.com - Investing.com India

Jun 18, 2025
pulisher
Jun 13, 2025

Adverum Biotechnologies’ SWOT analysis: gene therapy stock faces pivotal year - Investing.com Nigeria

Jun 13, 2025
pulisher
Jun 06, 2025

Adverum Biotechnologies Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4) - GlobeNewswire

Jun 06, 2025
pulisher
Jun 06, 2025

Adverum Biotechnologies (NASDAQ:ADVM) versus Metagenomi (NASDAQ:MGX) Head-To-Head Analysis - Defense World

Jun 06, 2025
pulisher
Jun 05, 2025

Adverum Awards 14,610 Shares in Stock Options and RSUs to Key New Hires - Stock Titan

Jun 05, 2025
pulisher
May 16, 2025

Adverum Biotechnologies Reports Q1 2025 Financial Results - TipRanks

May 16, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Sees Price Target Adjustment by RBC Capital | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Receives Continued Buy Rating from Chardan Capital | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Price Target Reduced by RBC Capit - GuruFocus

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies (ADVM) Rating Reiterated at 'Buy' by HC Wainwright | ADVM Stock News - GuruFocus

May 15, 2025
pulisher
May 15, 2025

RBC Cuts Price Target on Adverum Biotechnologies to $4 From $5, Keeps Sector Perform, Speculative Risk - marketscreener.com

May 15, 2025
pulisher
May 15, 2025

Adverum Biotechnologies: Q1 Earnings Snapshot - CT Insider

May 15, 2025
pulisher
May 14, 2025

Adverum (ADVM) Projects Funding Through Late 2025 | ADVM Stock N - GuruFocus

May 14, 2025
pulisher
May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline Highlights - The Manila Times

May 14, 2025
pulisher
May 14, 2025

Adverum Biotechnologies Reports First Quarter 2025 Financial Results and Provides Pipeline ... - Bluefield Daily Telegraph

May 14, 2025
pulisher
May 14, 2025

Revolutionary One-Time Gene Therapy Shows 3.5-Year Vision Protection in Wet AMD Patients - Stock Titan

May 14, 2025
pulisher
May 07, 2025

Adverum Biotechnologies Inc (ADVM)’s Market Momentum: Closing Strong at 3.23, Down -10.03 - DWinneX

May 07, 2025
pulisher
May 07, 2025

Adverum Biotechnologies’ SWOT analysis: gene therapy firm faces pivotal year - Investing.com Nigeria

May 07, 2025
pulisher
May 06, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc.ADVM - PR Newswire

May 06, 2025
pulisher
May 06, 2025

Adverum Biotechnologies' SWOT analysis: gene therapy firm faces pivotal year - Investing.com

May 06, 2025
pulisher
May 05, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum ... - Bluefield Daily Telegraph

May 05, 2025
pulisher
May 05, 2025

Adverum Biotechnologies Inc expected to post a loss of $1.94 a shareEarnings Preview - TradingView

May 05, 2025
pulisher
May 02, 2025

Adverum Biotechnologies Awards Strategic Stock Options Worth $108,000 to Expand Team - Stock Titan

May 02, 2025
pulisher
May 02, 2025

It makes sense and dollars to buy Adverum Biotechnologies Inc (ADVM) stock - Sete News

May 02, 2025
pulisher
Apr 30, 2025

Adverum Biotechnologies Inc: Navigating Market Volatility with a 1.79 Debt-to-Equity Ratio - investchronicle.com

Apr 30, 2025
pulisher
Apr 28, 2025

Adverum Biotechnologies Inc [ADVM] Investment Guide: What You Need to Know - knoxdaily.com

Apr 28, 2025
pulisher
Apr 28, 2025

Should investors be concerned about Adverum Biotechnologies Inc (ADVM)? - uspostnews.com

Apr 28, 2025
pulisher
Apr 28, 2025

Gaining Ground: Adverum Biotechnologies Inc (ADVM) Closes Lower at 2.91, Down -2.02 - DWinneX

Apr 28, 2025
pulisher
Apr 26, 2025

Press Release Distribution & PR Platform - ACCESS Newswire

Apr 26, 2025
pulisher
Apr 24, 2025

Hedge Fund and Insider Trading News: Ken Griffin, Steve Cohen, Scott Bessent, Balyasny Asset Management, Bridgewater Associates, Starboard Value, Maverick Capital, Kodai Capital Management, Antara Capital, Adverum Biotechnologies Inc (ADVM), and - Insider Monkey

Apr 24, 2025
pulisher
Apr 24, 2025

Adverum Biotechnologies Insider Bought Shares Worth $1,048,950, According to a Recent SEC Filing - marketscreener.com

Apr 24, 2025
pulisher
Apr 24, 2025

Adverum Biotechnologies Insider Buys 350,000 Shares - TradingView

Apr 24, 2025
pulisher
Apr 23, 2025

Adverum Biotechnologies Inc (ADVM) is an excellent investment, but the stock is overvalued/undervalued right now - uspostnews.com

Apr 23, 2025
pulisher
Apr 23, 2025

Trading Day Triumph: Adverum Biotechnologies Inc (ADVM) Ends at 2.96, a 8.42 Surge/Plunge - DWinneX

Apr 23, 2025
pulisher
Apr 21, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Stockholders to Inquire about Securities Investigation - markets.businessinsider.com

Apr 21, 2025
pulisher
Apr 21, 2025

Truist Removes $40 Price Target on Adverum Biotechnologies, Cites Share Volatility, Keeps Buy Rating - marketscreener.com

Apr 21, 2025
pulisher
Apr 20, 2025

Bronstein, Gewirtz & Grossman, LLC Encourages Adverum Biotechnologies, Inc. (ADVM) Investors to Inquire about Securities Investigation - markets.businessinsider.com

Apr 20, 2025
pulisher
Apr 18, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Investors to Reach Out - markets.businessinsider.com

Apr 18, 2025
pulisher
Apr 18, 2025

Adverum Biotechnologies (NASDAQ:ADVM) Earns Buy Rating from HC Wainwright - Defense World

Apr 18, 2025
pulisher
Apr 17, 2025

Bronstein, Gewirtz & Grossman, LLC Initiates an Investigation into Allegations Against Adverum Biotechnologies, Inc. (ADVM) And Encourages Stockholders to Reach Out - markets.businessinsider.com

Apr 17, 2025
pulisher
Apr 17, 2025

INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Adverum Biotechnologies, Inc. - GlobeNewswire Inc.

Apr 17, 2025

Finanzdaten der Adverum Biotechnologies Inc-Aktie (ADVM)

Umsatz

loading

Nettogewinn

loading

Free Cashflow

loading

ENV

loading

Adverum Biotechnologies Inc-Aktie (ADVM) Insiderhandel

Insiderhandel Beziehung Datum Transaktion Kosten #Aktien Wert ($) #Aktien Gesamt
Seyedkazemi Setareh
CHIEF DEVELOPMENT OFFICER
May 15 '25
Sale
2.00
924
1,848
13,768
Fischer Laurent
CEO, PRESIDENT AND DIRECTOR
May 15 '25
Sale
2.00
9,126
18,252
87,488
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 27 '25
Buy
5.19
16,593
86,089
141,800
Leonard Braden Michael
10% Owner
Apr 22 '25
Buy
3.00
300,000
900,000
3,057,526
Leonard Braden Michael
10% Owner
Apr 23 '25
Buy
2.98
50,000
148,950
191,800
Leonard Braden Michael
10% Owner
Mar 31 '25
Buy
4.38
19,566
85,668
2,742,317
Leonard Braden Michael
10% Owner
Apr 02 '25
Buy
4.04
15,209
61,408
2,757,526
Leonard Braden Michael
10% Owner
Mar 26 '25
Buy
5.04
20,407
102,841
125,207
Leonard Braden Michael
10% Owner
Mar 18 '25
Buy
4.69
62,341
292,418
2,667,161
$20.73
price up icon 1.02%
$35.27
price down icon 1.78%
$21.32
price up icon 0.24%
$101.74
price down icon 2.97%
$106.14
price up icon 1.28%
biotechnology ONC
$254.49
price down icon 4.73%
Kapitalisierung:     |  Volumen (24h):